TCTR20190428001已完成1 期
A Randomized, Single-Dose, Two-way Crossover, Open-label Study to Evaluate the Pharmacokinetics of Etoricoxib Tablet 120 mg and Arcoxia(R) 120 mg in Healthy Thai Subjects under Fasting Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Male/Female must be 18-55 years of age, body mass index (BMI) = 18.0-25.0 kg/m2, inclusive.
- •2.Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 129 mmHg, diastolic blood pressure not lower than 60 or not over 79 mmHg) , body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of clinical investigator
- •3.Screening electrocardiography (ECG) without clinically significant abnormalities
- •4.Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), Creatinine (Cr) analysis, lactic dehydrogenase (LDH), lactic acid, sodium (Na+), potassium (K+), chloride (Cl-), biocarbonate (CO2) and liver function test (aspartate aminotransferase (AST)/alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total protein, albumin, total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •5.Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •6.Must have serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus antibody (anti-HIV) seronegative
- •7.Female subjects must have beta-subunit of human chorionic gonadotropin in serum (β-HCG) negative.
- •8.Female subject who is childbearing potential or male subject agree to use an acceptable birth control method from visit 1 to the follow up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device (IUD) and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow up visit. Hormonal contraceptives are not acceptable.
- •9.Female subject who is non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea))
- •10.Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at period I and period II.
- •11.Non-smokers (never smoked or no smoking within the previous 1 years)
- •12.Refrain from using herbal medications, dietary supplements (e.g., St. John’s Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of study drug (Day 1). Subjects must agree to refrain from these items until the last collection time-point of period II.
- •13.Subjects must have ended any medications at least 30 days prior to Day 1 and agree to continue their refraining throughout the follow up period.
- •14.Subjects must refrain from drinking caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of period II.
- •15.Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by a
排除标准
- •1.Known hypersensitivity to etoricoxib, any other similar class of drugs and its components
- •2.Past medical history of renal and hepatic insufficiency
- •3.Subject has a history of any illness that, in the opinion of the investigator, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4.Subjects with stomatitis and glossitis that may affect buccal absorption of investigational drugs.
- •5.Subjects with an unhealed wound after tooth extraction or a wound on the tongue or oral mucosa.
- •6.Have history of drug abuse (in the opinion of the investigator, as judged by medical history) in the last 12 months.
- •7.Have positive result of urine drug abuse testing on opioids (morphine (Mor), methadone (MTD)), cannabinoids (tetrahydrocannabinol (THC)), methamphetamine (Meth), cocaine (Coc) and methylenedioxy-methamphetamine (MDMA) at screening visit or before dose administration at each period
- •8.Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months.
- •9.Have positive result of alcohol breathing test at screening visit or before dose administration at each period
- •10.Female subject is pregnant or breast feeding.
- •11.Difficulties fasting or consuming standard meals
- •12.Difficulties swallowing whole tablets
- •13.Donation or loss of whole blood:
- •a.≥ 50 mL and ≤ 499 mL within 30 days prior to dosing
- •b.≥ 500 mL within 56 days prior to dosing.
- •14.Participation in any investigation drug study within 1 month prior to screening visit.
研究者
相似试验
已完成
1 期
Randomized, Single-Dose, Two-Way Crossover, Open-Label Study to Evaluate Pharmacokinetics of Caliberi® Orodispersible Film 20 mg and Cialis® Tablet 20 mg in Healthy Male Thai Subjects under Fasting ConditionsTherapeutic EquivalenceTCTR20161031001Abbott Healthcare Products B.V.36
尚未招募
1 期
Randomized, Single-Dose, Two-Way Crossover, Open-Label Study to Evaluate Pharmacokinetics of Bucretis® Orodispersible Film 1.0 mg and Baraclude® Tablet 1.0 mg in Healthy Thai Subjects under Fasting ConditionsTherapeutic EquivalencyHealthy volunteerTCTR20161029001Abbott Healthcare Products B.V.28
尚未招募
1 期
Randomized, Single-Dose, Two-Way Crossover, Open-Label Study into the Bioequivalence of Esomeprazole Film Coated Tablet 20 mg and Nexium® Tablet 20 mg in Healthy Thai SubjectsBioequivalence study in healthy subjectsTCTR20161101002Abbott Healthcare Products B.V., The Netherlands112
尚未招募
1 期
Randomized, Single-Dose, Two-Way Crossover, Open-Label Study into the Bioequivalence of Esomeprazole Film Coated Tablet 40 mg and Nexium® Tablet 40 mg in Healthy Thai SubjectsBioequivalence study in healthy subjectsTCTR20161031002Abbott Healthcare Products B.V., The Netherlands112
进行中（未招募）
1 期
A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.hypertensionCTIS2024-514456-32-00Zaklady Farmaceutyczne Polpharma S.A.72